Cagrilintide – Comprehensive Research Overview (2026)
Cagrilintide is a long-acting synthetic analog of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. It is designed to complement GLP-1 receptor agonists by targeting the amylin receptor pathway, providing additive effects on appetite suppression, gastric emptying, and body weight reduction. Cagrilintide is being developed by Novo Nordisk and is currently in Phase 3 trials as a combination therapy with semaglutide (CagriSema) for obesity and type 2 diabetes.
→ View Cagrilintide (for laboratory research use only)
Mechanism of Action
Cagrilintide acts as a long-acting amylin receptor agonist:
- Activates amylin receptors in the area postrema and hypothalamus to suppress appetite and reduce food intake.
- Slows gastric emptying, prolonging satiety signals.
- Complements GLP-1 receptor agonism through distinct but synergistic pathways.
- Reduces glucagon secretion and improves postprandial glucose control.
Clinical Evidence and Research Findings
Phase 2 trials of cagrilintide alone demonstrated dose-dependent weight loss of up to 10.8% over 26 weeks. In combination with semaglutide (CagriSema), Phase 2 data showed weight reductions of up to 15.6% at 32 weeks, with Phase 3 trials (REDEFINE program) ongoing. It represents one of the most promising next-generation obesity therapies in development.
→ Interested in researching Cagrilintide? View Product Options
Benefits (Research & Clinical Observations)
- Significant body weight reduction via dual appetite suppression pathways
- Improved glycemic control and reduced postprandial glucose
- Synergistic effects with GLP-1 receptor agonists
- Once-weekly dosing convenience
Typical Dosing Protocols (Research / Clinical Trials)
- Clinical trial doses: 0.3–2.4 mg subcutaneous once weekly
- Titration schedules used to minimize GI side effects
- Often studied in combination with semaglutide 2.4 mg weekly
Safety Profile and Side Effects
Common side effects: Nausea, vomiting, diarrhea, constipation (similar to GLP-1 agonists). Injection-site reactions. Generally well-tolerated with titration.
Monitoring recommended: GI tolerance, renal function, and metabolic markers.
Cagrilintide vs Semaglutide vs Tirzepatide – Quick Comparison
| Aspect | Cagrilintide | Semaglutide | Tirzepatide |
|---|---|---|---|
| Mechanism | Amylin receptor agonist | GLP-1 receptor agonist | GLP-1 + GIP dual agonist |
| Weight Loss | ~10% alone; ~15%+ with sema | ~15% (Wegovy) | ~20%+ (Zepbound) |
| FDA Status | Phase 3 (not approved) | Approved (obesity, T2D) | Approved (obesity, T2D) |
Summary
Cagrilintide is a next-generation amylin analog with compelling Phase 2 data for weight loss, particularly in combination with semaglutide. Its complementary mechanism to GLP-1 agonists positions it as a potential cornerstone of future obesity pharmacotherapy. As with all compounds in this library, Cagrilintide is not yet an approved drug and should only be considered under qualified medical supervision.
For Laboratory Research Use View Cagrilintide →
Disclaimer This overview is strictly educational and based on publicly available scientific literature and regulatory information as of April 2026. It does not constitute medical advice, endorsement, or encouragement of use. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.